Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

1.

Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents.

Connolly DC, Hensley HH.

Curr Protoc Pharmacol. 2009 Jun;Chapter 14:Unit14.12. doi: 10.1002/0471141755.ph1412s45.

PMID:
22294392
[PubMed - indexed for MEDLINE]
2.

Genetic analysis of the early natural history of epithelial ovarian carcinoma.

Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, Robson ME, Offit K, Barakat RR, Boyd J.

PLoS One. 2010 Apr 26;5(4):e10358. doi: 10.1371/journal.pone.0010358.

PMID:
20436685
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.

Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC.

PLoS One. 2009 Dec 31;4(12):e8404. doi: 10.1371/journal.pone.0008404.

PMID:
20046879
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.

Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC.

PLoS One. 2009 Dec 31;4(12):e8534. doi: 10.1371/journal.pone.0008534.

PMID:
20046869
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.

Curran MA, Allison JP.

Cancer Res. 2009 Oct 1;69(19):7747-55. doi: 10.1158/0008-5472.CAN-08-3289. Epub 2009 Sep 8.

PMID:
19738077
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging.

Toyoshima M, Tanaka Y, Matumoto M, Yamazaki M, Nagase S, Sugamura K, Yaegashi N.

Luminescence. 2009 Sep-Oct;24(5):324-31. doi: 10.1002/bio.1112.

PMID:
19711487
[PubMed - indexed for MEDLINE]
7.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

PMID:
19474385
[PubMed - indexed for MEDLINE]
Free Article
8.

ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.

Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J.

Mol Cancer Ther. 2009 Jan;8(1):64-74. doi: 10.1158/1535-7163.MCT-08-0864.

PMID:
19139114
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax.

Roby KF, Niu F, Rajewski RA, Decedue C, Subramaniam B, Terranova PF.

Adv Exp Med Biol. 2008;622:169-81. Review. No abstract available.

PMID:
18546627
[PubMed - indexed for MEDLINE]
10.

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.

Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP.

Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3509-14. doi: 10.1073/pnas.0712269105. Epub 2008 Feb 26.

PMID:
18303116
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.

Greenaway J, Moorehead R, Shaw P, Petrik J.

Gynecol Oncol. 2008 Feb;108(2):385-94. Epub 2007 Nov 26.

PMID:
18036641
[PubMed - indexed for MEDLINE]
12.

Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer.

Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC.

Cancer Biol Ther. 2007 Nov;6(11):1717-25. Epub 2007 Aug 3.

PMID:
17986851
[PubMed - indexed for MEDLINE]
Free Article
13.

Normalization of the ovarian cancer microenvironment by SPARC.

Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K.

Mol Cancer Res. 2007 Oct;5(10):1015-30.

PMID:
17951402
[PubMed - indexed for MEDLINE]
Free Article
14.

Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion.

Du YC, Lewis BC, Hanahan D, Varmus H.

PLoS Biol. 2007 Oct 16;5(10):e276.

PMID:
17941720
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.

Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, Li MC, Demayo FJ, Linnoila I, Deng CX, Lee EY, Medina D, Shih JH, Green JE.

Cancer Res. 2007 Sep 1;67(17):8065-80. Erratum in: Cancer Res. 2007 Oct 15;67(20):10097.

PMID:
17804718
[PubMed - indexed for MEDLINE]
Free Article
16.

Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis.

Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR.

Mol Cancer Ther. 2007 Jul;6(7):1993-2002.

PMID:
17620429
[PubMed - indexed for MEDLINE]
Free Article
17.

Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR.

Cancer Cell. 2007 Apr;11(4):321-33.

PMID:
17418409
[PubMed - indexed for MEDLINE]
Free Article
18.

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR.

Cancer Res. 2007 Mar 15;67(6):2408-13.

PMID:
17363557
[PubMed - indexed for MEDLINE]
Free Article
19.

The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9. Review.

PMID:
17218844
[PubMed - indexed for MEDLINE]
20.

Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31. Epub 2006 Nov 6.

PMID:
17088539
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk